BCG vaccine-associated suppurative lymphadenitis

Clusters of BCG vaccine-associated suppurative lymphadenitis (BCG-ASLD) have been reported in many countries. We have observed an increase in BCG-ASLD following the change from the percutaneous Evans vaccine to the intradermal BCG Statens Serum Institute (SSI) vaccine.

Saved in:
Bibliographic Details
Published in:Vaccine 2005-04, Vol.23 (20), p.2676-2679
Main Authors: Teo, Stephen S.S., Smeulders, Naima, Shingadia, Delane V.
Format: Article
Language:English
Subjects:
Adjuvants, Immunologic - administration & dosage
Adjuvants, Immunologic - adverse effects
Age
Applied microbiology
Bacteria
Bacterial diseases
BCG
BCG Vaccine - administration & dosage
BCG Vaccine - adverse effects
Biological and medical sciences
Chemotherapy
Female
Fundamental and applied biological sciences. Psychology
Genetic diversity
Human bacterial diseases
Humans
Infant
Infectious diseases
Injections, Intradermal
Injections, Subcutaneous
London - epidemiology
Lymphadenitis
Lymphadenitis - epidemiology
Lymphadenitis - etiology
Male
Medical sciences
Microbiology
Morbidity
Population
Tuberculosis
Tuberculosis and atypical mycobacterial infections
Vaccine
Vaccines
Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Clusters of BCG vaccine-associated suppurative lymphadenitis (BCG-ASLD) have been reported in many countries. We have observed an increase in BCG-ASLD following the change from the percutaneous Evans vaccine to the intradermal BCG Statens Serum Institute (SSI) vaccine.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2004.07.052